Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study

Youquan Li1,2, Whee Sze Ong3, Ma Than Than Shwe1, Nelson Ling Fung Yit1, Sheriff Zhan Hong Quek1, Eric Pei Ping Pang1, Wen Shen Looi1,2, Wen Long Nei1,2, Michael Lian Chek Wang1,2, Melvin Lee Kiang Chua1,2, Terence Wee Kiat Tan1,2, Eu Tiong Chua1,2, Choon Ta Ng2,4 and Jeffrey Kit Loong Tuan1,2*

Abstract

Background: Androgen deprivation therapy (ADT) and radiotherapy (RT) are the mainstay treatment for localized prostate cancer and recurrence after surgery. Cardiovascular (CV) toxicity of ADT is increasingly recognized, and the risk relates to pre-existing risk factors and ADT modalities. Despite ethnic differences in the prevalence of CV risk factors and variations of CV mortality, data on ADT-related cardiotoxicities in the Asian population remain inconclusive. Our registry-based study investigated ADT-related major adverse cardiovascular events (MACE) after primary or salvage RT.

Methods: Our study combined two prospectively established registry databases from National Cancer Center Singapore and National Heart Center Singapore. The primary endpoint is time to first MACE after treatment. MACE is defined as myocardial infarction, stroke, unstable angina, or cardiovascular death. Two types of propensity score adjustments, including ADT propensity score as a covariate in the multivariable regression model and propensity score weighting, were applied to balance baseline features and CV risk factors between RT alone and RT + ADT groups.

Results: From 2000 to 2019, 1940 patients received either RT alone (n = 494) or RT + ADT (n = 1446) were included. After a median follow-up of 10 years (RT) and 7.2 years (RT + ADT), the cumulative incidence of MACE at 1, 3 and 9 years was 1.2, 5 and 16.2% in RT group, and 1.1, 5.2 and 17.6% in RT + ADT group, respectively. There were no differences in the incidence of MACE between 2 groups (HR 1.01, 95% CI 0.78–1.30, p = 0.969). Pre-treatment CV risk factors were common (80%), and CV disease (15.9%) was the second leading cause of death after prostate cancer (21.1%). On univariate analysis, older age, Indians and Malays, pre-existing CV risk factors, and history of MACE were associated with higher MACE risk. After propensity score adjustments, there remained no significant differences in MACE risk between RT + ADT and RT group on multivariable analysis.

Conclusions: In our registry-based study, ADT is not associated with increased risk of major cardiovascular events among Southeast Asian men with prostate cancer after curative radiotherapy.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Since the effect of castration on serum phosphatases in prostate cancer patients was first reported in 1941, androgen-deprivation therapy (ADT) has become the mainstay treatment for advanced and metastatic prostate cancer. Combined with radiotherapy (RT), ADT has been shown in several randomized trials to improve survival in intermediate- and high-risk localized disease, as well as locally advanced and node-positive disease [1–6]. However, ADT also causes a wide range of metabolic side effects including obesity, insulin resistance, and lipid alterations that contribute to cardiovascular (CV) risks.

Patients received curative radiotherapy are often diagnosed at an advanced age, and preexisting CV risk factors are common. ADT is most commonly given in the form of gonadotrophin-releasing hormone (GnRH) agonist with radiotherapy. In several retrospective studies, GnRH agonist is associated with higher CV risk compared with orchiectomy and GnRH antagonists [7–9]. Recent HERO trial reported a significant 54% reduction in new cardiovascular events for the oral GnRH-antagonist compared with the GnRH-agonist in advanced prostate cancer [7].

Cardiovascular disease has become the leading cause of death in men with prostate cancer in the United States [10]. Cardiovascular disease and cancer are the first and second most common cause of death in Singapore and the leading contributors to the burden of disease. A growing body of evidence demonstrates racial and ethnic disparities in the prevalence of CV risk factors and variations of CV mortality in the general population [11]. Ethnicity also impacts prostate cancer-specific outcomes of men with metastatic hormone-sensitive prostate cancer [12]. The ethnic differences of prostate cancer and cardiovascular disease both could be attributed to distinct biological, social, and environmental factors. However, data on ADT-related CV toxicities in the Asian prostate cancer population remains scanty and inconclusive [13–15]. The current study used real-world registry data to assess the association of ADT and major CV events in the Southeast Asian prostate cancer population treated with curative radiotherapy.

Methods
Patients
Outcomes Research in DRO Cancer Care (“Outcomes Study”) (CIRB ref.: 2016/2020/B) is a prospectively established registry database at National Cancer Centre Singapore. Outcomes Study collects comprehensive real-world data (RWD) through Electronic Medical Record (EMR) and patient-reported outcomes (PRO) during cancer patients’ entire treatment and follow-up period. Singapore Cardiac Data Bank (SCDB) was established in 2000 as a national data bank of cardiovascular diseases and procedures (NIH: NCT03760705). SCDB modules include various intervention procedures and cardiac surgery [16, 17]. Individual data from two registry databases were combined via a unique national identification number.

The current study included Singapore male residents with non-metastatic prostate cancer who started treatment from January 2000 to September 2019. Initial data collection of medical history was made by the treating radiation oncologist at the first consultation. Physicians systemically assessed cardiovascular risk factors including Body Mass Index (BMI), smoking history, diabetes mellitus, hypercholesterolemia, hypertension, stroke, coronary artery disease, type of intervention or surgery for cardiac conditions, medications, and other significant cardiac histories through EMR and history taking. New cardiovascular events after treatment and cause of death were verified by board certified cardiologists.

The decision on ADT was made by oncologists according to D’Amico risk classification in localized disease or pathological findings and PSA after radical prostatectomy [1, 4, 18]. ADT included GnRH antagonists and GnRH agonists with or without short-term anti-androgen therapy for testosterone flare prevention. Men who underwent orchiectomy were excluded. Primary radiation regimens included conventional fractionation (74–78 Gy, 1.8–2.0 Gy per fraction), moderate hypofractionation (60 Gy, 2.5–4.0 Gy per fraction) or ultra-hypofractionation (>5.0 Gy per fraction). Conventional fractionation (66 Gy, 2.0 Gy per fraction) was given as adjuvant or salvage radiotherapy after radical prostatectomy.

Outcome measure and assessments
The primary endpoint was time to first Major Adverse Cardiovascular Events (MACE) after the start of treatment for prostate cancer. MACE was defined as myocardial infarction, stroke, unstable angina requiring intervention, or cardiovascular death. The start date of treatment was defined as the start of ADT for patients who had received RT and ADT (RT + ADT) and the start of RT for RT only patients. Time to MACE was censored at the initiation of palliative systemic therapy (ADT, other
hormonal agents, or chemotherapy) when patients developed recurrence or metastases. Alive or lost to follow-up patients without recurrence, metastases or MACE were censored at their date of the last follow-up.

Statistical analysis
Baseline characteristics of the two treatment groups were compared using the Chi-square or Fisher’s exact test for categorical variables and Mann-Whitney U test for continuous variables. A competing risk approach was used to estimate the cumulative incidence of MACE as the cause of failure, with deaths due to non-cardiovascular causes as competing events. Comparison of cumulative incidence curves was made using the Gray’s test.

Univariate and multivariable Fine and Gray’s regression model was used to examine the association of ADT and other covariates with time to first MACE. Variables with univariate $p<0.05$ were included in the multivariable model. Proportional hazard (PH) assumption was verified for each variable included in the multivariable model by including a time-by-variable interaction term for each variable.

Sensitivity analysis was performed to assess the impact of unbalanced baseline characteristics on the association of ADT with the risk of MACE via 2 types of propensity score adjustments. The first adjustment was made by including the probability of receiving ADT ($p$) as a covariate in the multivariate Fine and Gray’s regression model for time to first MACE. The second adjustment was made via propensity score weighting where each RT only patient was assigned a weight of $(1/p)$ and each RT + ADT patient was assigned a weight of $(1/(1-p))$. The probability of receiving ADT was derived based on a logistic regression analysis with all baseline characteristics included as covariates in the model. Goodness of fit and discrimination ability of the fitted logistic model were assessed based on the Hosmer-Lemeshow test and area under the receiver operating characteristics curve (AUC), respectively. All statistical analyses were performed using Stata 15.0. Statistical significance was defined as 2-sided $p<0.05$.

Results
The study cohort consisted of 1940 patients was analyzed, of which 494 received RT only and 1446 received RT + ADT. The baseline characteristics were summarized in Table 1. Majority ($n=1702$, 87.7%) received primary radiotherapy; 12.3% ($n=238$) were treated as salvage or adjuvant radiation. Among the RT + ADT patients, 96.9% ($n=1401$) received GnRH agonists (Goserelin, Leuprolelin & Triptorelin) and 61.5% ($n=889$) received more than 6 months’ hormonal treatment.

Table 1 Baseline Demographic and Treatment Characteristics

|                      | RT only (N = 494) | RT + ADT (N = 1446) | $p$ |
|----------------------|-------------------|---------------------|-----|
| Age at start of treatment, years |                   |                     |     |
| Median (range)       | 68 (49–94)        | 71 (46–89)          | <0.001 |
| Below 70             | 274 (55.5%)       | 650 (45.0%)         | <0.001 |
| 70 & over            | 220 (44.5%)       | 796 (55.0%)         |     |
| Ethnic group         |                   | 0.677               |     |
| Chinese              | 447 (90.5%)       | 1297 (89.7%)        |     |
| Malays               | 17 (3.4%)         | 66 (4.6%)           |     |
| Indians              | 20 (4.0%)         | 50 (3.5%)           |     |
| Others               | 10 (2.0%)         | 33 (2.3%)           |     |
| ECOG performance status |               |                     | 0.024 |
| 0–1                  | 493 (99.8%)       | 1425 (98.5%)        |     |
| 2–4                  | 1 (0.2%)          | 21 (1.5%)           |     |
| Gleason score        |                   | <0.001              |     |
| 6 or less            | 241 (48.8%)       | 177 (12.2%)         |     |
| 7                    | 197 (39.9%)       | 770 (53.3%)         |     |
| 8–10                 | 39 (7.9%)         | 485 (33.5%)         |     |
| Missing              | 17 (3.4%)         | 14 (1.0%)           |     |
| ISUP grade           |                   | <0.001              |     |
| 1                    | 241 (48.8%)       | 177 (12.2%)         |     |
| 2                    | 136 (27.5%)       | 451 (31.2%)         |     |
| 3                    | 61 (12.3%)        | 319 (22.1%)         |     |
| 4                    | 23 (4.7%)         | 207 (14.3%)         |     |
| 5                    | 16 (3.2%)         | 278 (19.2%)         |     |
| Missing              | 17 (3.4%)         | 14 (1.0%)           |     |
| D’Amico risk classification |               | <0.001              |     |
| Low                  | 174 (35.2%)       | 49 (3.4%)           |     |
| Intermediate         | 198 (40.1%)       | 419 (29.0%)         |     |
| High                 | 107 (21.7%)       | 973 (67.3%)         |     |
| Missing              | 15 (3.0%)         | 5 (0.3%)            |     |
| Radiation intent     |                   | <0.001              |     |
| Definitive radiation | 354 (71.7%)       | 1348 (93.2%)        |     |
| Salvage radiation    | 140 (28.3%)       | 98 (6.8)            |     |
| ADT type$^a$         |                   | NA                  |     |
| Agonist              | NA                 | NA (1401)           | 96.9 |
| Antagonist           | NA                 | NA (45)             | 3.1  |
| ADT duration         |                   | NA                  |     |
| 4–6 months           | NA                 | 557 (38.5%)         |     |
| >6 months            | NA                 | 889 (61.5%)         |     |
| Baseline CVD risk factor |               | 0.010               |     |
| At least one         | 386 (78.1%)       | 1209 (83.6%)        |     |
| None                 | 83 (16.8%)        | 196 (13.6%)         |     |
| Missing              | 25 (5.1%)         | 41 (2.8)            |     |
| Previous history of MACE |               | 0.127               |     |
| No                   | 398 (80.6%)       | 1113 (77.0%)        |     |
| Yes                  | 95 (19.2%)        | 332 (23.0%)         |     |
| Missing              | 1 (0.2%)          | 1 (0.1)             |     |

ECOG Eastern Cooperative Oncology Group, ISUP International Society of Urological Pathology, CVD Cardiovascular disease, NA Not applicable

$^a$ Agonist included goserelin, leuprorelin & triptorelin; antagonist included degarelix
Preexisting cardiovascular risk factors were common in our study population. Over 80% of the patients had at least one risk factor across the three main domains: lifestyle (such as smoking and obesity defined as BMI > 27.5), cardiovascular (such as diabetes, dyslipidemia, and hypertension), and history of MACE. CV risk factors were more common in RT + ADT patients (83.6% versus 78.1%, \( p = 0.010 \)), on account of the higher percentage of patients in this group with hypertension, dyslipidemia and diabetes (Supplementary Table SA1). Statins were also more commonly taken by RT + ADT patients (42.8% versus 35.2%, \( p = 0.002 \)) (Supplementary Table SA2). About 1 in 5 patients in both RT alone (19%) and RT + ADT group (23%) had a previous history of MACE.

The median follow-up duration was 10 years (95% CI, 9.2–10.7 years) for RT alone group and 7.2 years (95% CI, 6.9–7.5 years) for RT + ADT group. This could be attributed to the higher incidence of deaths over time within the RT + ADT patients. The risk of all causes mortality amongst RT + ADT group was 1.23 times (95% CI 0.99–1.52) that of RT alone group (Supplement Table SA6). The RT + ADT group had higher risk of prostate cancer deaths (Sub distribution HR [SHR] 1.14, 95% CI 0.72–1.80, \( p = 0.574 \)), as well as other deaths not related to prostate cancer and CV diseases (SHR 1.26, 95% CI 0.96–1.66, \( p = 0.094 \)) than RT alone group.

The cumulative incidence of new MACE at 1, 3 and 9 years was 1.2, 5 and 16.2% in RT alone group, and 1.1, 5.2 and 17.6% in RT + ADT group, respectively (SHR 1.01, 95% CI 0.78–1.30, \( p = 0.969 \)) (Fig. 1A). Myocardial infarction was the most common type of event in both groups (75% in RT and 66.5% in RT + ADT) (Supplement Table SA7). Subgroup analyses suggested that the risk of MACE by treatment groups did not vary by presence of baseline CV risk factor (None: SHR 1.49, 95% CI 0.56–3.97 vs At least one risk factor: SHR 0.99, 95% CI 0.75–1.31, interaction \( p = 0.431 \)) (Fig. 1B) and history of MACE (No: SHR 1.09, 95% CI 0.79–1.50 vs Yes: SHR 0.79, 95% CI 0.51–1.21, interaction \( p = 0.238 \)) (Fig. 1C). The cumulative incidence of MACE among patients with a history of MACE was numerically higher amongst the RT + ADT group than that of the RT alone group for the first few years after treatment, however, the difference was not statistically significant (\( p = 0.228 \)). In particular, the incidence of new MACE at 1, 2 and 3 years was 3.2, 5.4, and 7.9% in the RT group, and 3.0, 6.5, and 11.7% in the RT + ADT group, respectively. In terms of mortality, cardiovascular disease was the second most common cause of death (17.8%) after prostate cancer (21.1%) (Supplementary Table SA6).
On univariate analysis, older age (above 70), Malays and Indians (relative to Chinese), baseline CV risk factor and GnRH antagonist were associated with greater CV risk (Table 2). Patients with a history of MACE were also more likely to develop new MACE after treatment for prostate cancer (HR 2.05, 95% CI, 1.61–2.63; \( p < 0.001 \)). Adjusting for all statistically significant factors in univariate analysis, there remained no significant differences in the risk of MACE between RT + ADT and RT groups on multivariable analysis.

In sensitivity analysis, the probability of receiving ADT was significantly associated with age, Gleason score, and D’Amico risk classification (Supplementary Table SA3). The fitted logistic model has a good fit (\( p = 0.409 \)) and a high discrimination ability (AUC = 0.812). The conclusion that ADT was not associated with the risk of MACE from the main analysis remained unchanged in both propensity score adjustments (Supplementary Table SA4 and SA5).

**Discussion**

In high-risk and locally advanced prostate cancer, ADT is an essential component combined with curative radiotherapy [2–4]. Several retrospective studies, mainly in the Caucasian population, suggested an increased risk of CV events in men who received GnRH agonist [7–9]. However, results of the CV toxicities of ADT in the Asian population are inconclusive. Teoh et al. reported ADT increased the risk of myocardial infarction and ischemic stroke compared with the non-ADT group in Chinese prostate cancer patients [13, 14]. However, a population study from Japan reported similar cardiovascular mortality after GnRH agonist compared with estimated mortality in the general population [15]. Another Taiwanese study reported similar incidence of coronary heart disease between men who did or did not receive ADT [19].

Cardiovascular disease is the leading cause of non-cancer deaths in men with prostate cancer. The incidence of secondary CV events after ADT varies greatly depending on underlying CV risk factors. A longitudinal study (RADICAL PC) reported that two-thirds of a cohort of 2492 men with prostate cancer had high CV risk with 22% having established CV disease [20]. In our cohort, 80% of men had at least one CV risk factor, and 20% had previous history of MACE. PRONOUNCE is the first prospective randomized study comparing CV safety of GnRH antagonist and agonist mainly in men with history of cardiac disorders. The study was

| Table 2 Univariate and multivariable analysis of MACE after start of treatment |
|-----------------------------------|------------------|------------------|------------------|------------------|
| Treatment group: RT + ADT vs RT only | 1.01 (0.78–1.30) | 0.969            | 0.95 (0.73–1.25) | 0.722 |
| Age (years): 70 & over vs below 70 | 1.41 (1.12–1.78) | 0.004            | 1.35 (1.05–1.72) | 0.018 |
| Ethnic group: Malays vs Chinese | 1.66 (1.04–2.65) | 0.033            | 1.53 (0.93–2.51) | 0.095 |
| Ethnic group: Indians vs Chinese | 2.15 (1.38–3.35) | 0.001            | 1.79 (1.11–2.87) | 0.016 |
| Ethnic group: Others vs Chinese | 1.37 (0.62–3.04) | 0.436            | 1.57 (0.69–3.58) | 0.282 |
| Gleason score: 7 vs 6 or less | 0.99 (0.75–1.30) | 0.919            |                  |      |
| Gleason score: 8–10 vs 6 or less | 1.03 (0.74–1.43) | 0.859            |                  |      |
| ISUP grade: 2 vs 1 | 1.03 (0.76–1.40) | 0.851            |                  |      |
| ISUP grade: 3 vs 1 | 0.92 (0.64–1.31) | 0.636            |                  |      |
| ISUP grade: 4 vs 1 | 0.96 (0.61–1.50) | 0.856            |                  |      |
| ISUP grade: 5 vs 1 | 1.08 (0.74–1.56) | 0.699            |                  |      |
| D’Amico risk: Intermediate vs Low | 0.87 (0.61–1.26) | 0.472            |                  |      |
| D’Amico risk: High vs Low | 0.99 (0.71–1.39) | 0.966            |                  |      |
| Previous history of MACE: Yes vs No | 2.05 (1.61–2.63) | < 0.001          | 1.75 (1.21–2.53) | 0.003 |
| Baseline CVD risk factor: ≥ 1 vs 0 | 2.53 (1.64–3.92) | < 0.001          | 1.73 (1.08–2.76) | 0.022 |
| Baseline metformin: Yes vs No | 1.94 (1.46–2.56) | < 0.001          | 1.56 (1.15–2.10) | 0.004 |
| Baseline insulin: Yes vs No | 3.10 (1.46–6.56) | 0.003            | 1.53 (0.68–3.45) | 0.310 |
| Baseline statins: Yes vs No | 1.61 (1.28–2.03) | < 0.001          | 1.21 (0.92–1.58) | 0.174 |
| Baseline antplatelet: Yes vs No | 1.61 (1.21–2.15) | 0.001            | 0.78 (0.53–1.15) | 0.213 |
| Baseline anticoagulant: Yes vs No | 1.82 (0.87–3.83) | 0.113            |                  |      |
| Surgery for IHD at baseline: Yes vs No | 1.99 (1.47–2.71) | < 0.001          | 1.15 (0.76–1.75) | 0.513 |
| Radiation intent: Definitive vs Salvage | 1.51 (0.98–2.32) | 0.063            |                  |      |

\( ISUP \) International Society of Urological Pathology, \( CVD \) Cardiovascular disease, \( IHD \) Ischemic heart disease
terminated prematurely due to slow accrual, and no difference in MACE was observed at 1 year (5.5% vs 4.1%, \(p = 0.53\)) between degarelix or leuprolide groups [21]. In the HERO trial, new MACE within 1 year after ADT was common in patients with CV risk factors (6.2%) and a history of MACE (17.8%) [7]. GnRH antagonist (Relugolix) significantly reduced new MACE (2.9% for antagonist versus 6.2% for agonist) during the safety analysis, and the risk reduction was more significant in men with previous MACE (3.6% versus 17.8%) [7]. In our study, despite the preexisting CV risk factors are common (80%), new MACE within the first year was low; 1.1% for the entire group and 3.0% for patients with previous MACE. No difference of new MACE was found between radiation alone and radiation + ADT. Similar to previous studies from Japan and Taiwan populations [15, 19], ADT was not found to increase secondary CV events in our cohort.

The different findings on ADT-related cardiotoxicities between our cohort and previous studies in Caucasian population could be multi-factorial. First, identifying men at risk for secondary CV events after ADT remains challenging. The current approach mainly relies on routine CV risk factors assessment. Novel cardiac blood biomarkers including N-terminal pro-B-type natriuretic peptide (NTproBNP) C-reactive protein (CRP), and high-sensitivity troponin (hsTn) are being evaluated to predict ADT-related CV toxicities [22]. Novel predictive cardiac biomarkers are urgently needed to identify men at risk and mitigate ADT-related cardiotoxicities. Second, awareness of CV risk factors and secondary prevention with cardio-protective agents also impact the incidence of secondary MACE. The association between GnRH agonists and CV events has been hypothesized to relate to the destabilization of existing vascular plaques. The common usage of statins in our study (42.8% in RT + ADT and 35.2% in RT alone) might contribute to a favorable low incidence of new MACE [23–25]. In our study, the cardiac events were independently confirmed by cardiologists rather than insurance coding. The duration of ADT with radiation limits to 3 years instead of lifelong and this could explain the similar long-term CV events between two groups. Last, androgen receptor genetic polymorphisms and variation of androgen and sex hormone-binding globulin levels among different ethnic groups maybe another reason leading to differences in cardiovascular profiles and metabolic response to testosterone suppression [11, 26, 27]. In a population study from the United States, non-Hispanic Asians had the lowest risk of cardiac mortality among different racial groups [27].

Our observational study does have several limitations and needs interpretation within context. First, there is an inherent limitation for all retrospective studies, and the selection for ADT was not randomly assigned. It remains possible preexisting CV risk factors affect the decision on choice and duration of ADT. To minimize the selection bias, we performed a sensitivity analysis with propensity score adjustment for unbalanced baseline characteristics, and the conclusion remains the same. Second, despite initial cardiovascular risk assessment by oncologists, further management of various risk factors was done by the primary care physicians or cardiologists. However, prescription information within the EMR of the public healthcare system accurately determines the duration of ADT and other medications for primary or secondary prevention of cardiovascular disease. Third, Singapore Cardiac Databank includes information from the public healthcare system and may under-represented some of CV events from private providers. However, the database includes 80% of hospital care delivered in public institutions and reflects the nationwide pattern of practice. The strengths of the current study are the large size and complete long-term follow-up in the Southeast Asian men with prostate cancer from two prospectively established registry databases. Compared with previous studies of the Chinese or Japanese population, our study included a more diversified multi-ethnic group from Southeast Asia.

Cardiotoxicities associated with anticancer therapies are increasingly recognized and the prevention remains challenging in cancer survivorship [28]. Excessive CV morbidity and mortality associated with systemic therapy and radiotherapy compromised the clinical benefits of anticancer treatment [29]. Close collaboration among oncologists, cardiologists, and primary care physicians ensures delivery of optimal cancer care without compromising CV health [28, 30, 31].

**Conclusions**

In our registry-based observational study, ADT was not found to be associated with increased risk of major cardiovascular event among Southeast Asian men received curative radiotherapy in two types of propensity score adjustments.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40959-022-00131-4.

**Additional file 1:** Table SA1. Baseline cardiovascular disease risk factor by treatment group. Table SA2. Baseline drug use and surgery/intervention for IHD by treatment group. Table SA3. Multivariable logistic regression of receiving RT + ADT treatment. Table SA4. Univariate and multivariable analysis of MACE after start of treatment with treatment propensity score included as a covariate. Table SA5. Univariate and multivariable analysis of MACE after start of treatment with treatment propensity score weighting. Table SA6. Cumulative Incidence Rate of Mortality by Causes. Table SA7. MACE by Type of Event.
Acknowledgements
The patients and families for participating in the study. Ferring Pharmaceuticals Provided Funding for Current Study.

Preparation and review of manuscript
All.

Authors’ contributions
Concept and design: YL, WSO, JKLT, CTN. Data collection and analysis: TSWM, NLFY, SZH, WJN, MLCC, MLKC, TWKT, ETC, CTN, WSL, EPPP. The author(s) read and approved the final manuscript.

Funding
The study is supported by a grant from Ferring Pharmaceuticals.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Not Applicable.

Ethics approval and consent to participate
The study is supported by a grant from Ferring Pharmaceuticals. Consent for publication Not Applicable.

Authors’ contributions
Concept and design: YL, WSO, JKLT, CTN. Data collection and analysis: TSWM, NLFY, SZH, WJN, MLCC, MLKC, TWKT, ETC, CTN, WSL, EPPP. The author(s) read and approved the final manuscript.

Funding
The study is supported by a grant from Ferring Pharmaceuticals.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Yes. The study is approved by the Singapore Central Institutional Review Board (CIRB) CIRB Ref 2016-2020/B.

Consent for publication
Not Applicable.

Competing interests
None.

Author details
1 Department of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610, Singapore. 2 Duke–NUS Graduate Medical School, Singapore, Singapore. 3 Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore. 4 Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.

Received: 19 October 2021 Accepted: 28 February 2022

Published online: 14 March 2022

References
1. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95. https://doi.org/10.1001/jama.299.3.289.
2. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107–18. https://doi.org/10.1056/NEJMoa1012348.
3. Denham M, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 06.01 randomised trial. Lancet Oncol. 2011;12(5):451–9. https://doi.org/10.1016/S1470-2045(11)70063-8.
4. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295–300. https://doi.org/10.1056/NEJM199703313370502.
5. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1 pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial radiation therapy oncology group 85-31. J Clin Oncol. 2005;23(4):800–7. https://doi.org/10.1200/JCO.2005.08.141 Erratum in: J Clin Oncol 2005 Dec 1;23(34):8921.
6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781–8. https://doi.org/10.1056/NEJM199910293412401.
7. Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–96. https://doi.org/10.1056/NEJMoa2004325 Epub 2020 May 29.
8. Nguyen PL. Androgen-deprivation therapy and cardiovascular harm: let us not throw out the baby with the bathwater. Eur Urol. 2014;65(4):710–2. https://doi.org/10.1016/j.eururo.2013.03.002 Epub 2013 Mar 13.
9. Thomsen FB, Sandin S, Garmo H, et al. Gonadotropin-releasing hormone agonists, orchectomity, and risk of cardiovascular disease: semi-ecologic Nationwide, Population-based Study. Eur Urol. 2017;72(6):920–8. https://doi.org/10.1016/j.eururo.2017.06.036 Epub 2017 Jul 12.
10. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–97. https://doi.org/10.1093/eurheartj/ehz766.
11. Chaturvedi N. Ethnic differences in cardiovascular disease. Heart. 2003;89(6):681–6. https://doi.org/10.1136/heart.89.6.681.
12. Bernard B, Muradihvar C, Chen YH, et al. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017;123(9):1536–44. https://doi.org/10.1002/cncr.30503 Epub 2017 Jan 5.
13. Teoh JY, Chan SY, et al. Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population. BJU Int. 2015;116(3):382–7. https://doi.org/10.1111/bju.12967 Epub 2015 Mar 7.
14. Teoh JY, Chiu PK, Chan SY, et al. Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol. 2015;45(5):483–7. https://doi.org/10.1093/jcnc/jocy025 Epub 2015 Feb 26.
15. Akaza H. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology. 2010;85(2):110–20. https://doi.org/10.1159/000174486 Epub 2010 Feb 30.
16. Sahlién A, Hamid N, Amanullah MR, et al. Impact of aortic root size on left ventricular afterload and stroke volume. Eur J Appl Physiol. 2016;116(7):1355–65. https://doi.org/10.1007/s00421-016-3392-0 Epub 2016 May 14.
17. Yap J, Chia SY, Lim FY, et al. The Singapore heart failure risk score: prediction of survival in southeast Asian patients. Ann Acad Med Singap. 2019;48(3):86–94.
18. Nabid A, Carrier N, Martin AG, et al. Duration of androgen deprivation therapy in high-risk prostate Cancer: a randomized phase III trial. Eur Urol. 2018;74(4):432–41. https://doi.org/10.1016/j.eururo.2018.06.018 Epub 2018 Jul 3.
19. Huang G, Yeung CY, Lee KK, et al. Androgen deprivation therapy and cardiovascular risk in Chinese patients with nonmetastatic carcinoma of prostate. J Oncol. 2014;2014:259426. https://doi.org/10.1155/2014/259426 Epub 2014 Apr 7.
20. Leong DP, Fradet V, Shayeagan B, et al. Cardiovascular risk in men with prostate Cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109–16. https://doi.org/10.1097/JCU.0000000000001714 Epub 2020 Jan 3. PMID: 31899651.
21. Melloni C, Slovin SF, Blemings A, et al. Cardiovascular safety of Degarelix versus Leuprolide for advanced prostate Cancer: the PRONOUNCE trial study design. JACC Cardio Oncol. 2020;2(1):70–81. https://doi.org/10.1016/j.jaccoa.2020.01.004 PMID: 34396210; PMCID: PMC8352040.
22. Margel D, Ber Y, Peer A, et al. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gondotrophin releasing hormone agonist vs antagonist. Prostate Cancer Prostatic Dis. 2020. https://doi.org/10.1038/s41391-020-0264-9.
23. Kalam K, Manwrick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2015;49(13):2900–9. https://doi.org/10.1016/j.ejca.2013.04.030 Epub 2013 May 22.
24. Hashman LC, Wang X, Nakabayashi M, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate Cancer. JAMA Oncol. 2015;1(4):495–504. https://doi.org/10.1001/jamaoncol.2015.0829 Erratum in: JAMA Oncol 2015 Jul;1(4):544.
25. Hamilton RJ, Ding K, Crook JM, et al. The association between statin use and outcomes in patients initiating androgen deprivation therapy. Eur J Cancer. 2008;44(12):1874–80. https://doi.org/10.1016/j.ejca.2008.04.006.
26. Hamilton RJ, Crook JM, et al. The association between statin use and outcomes in patients initiating androgen deprivation therapy. Eur J Cancer. 2008;44(12):1874–80. https://doi.org/10.1016/j.ejca.2008.04.006.
26. Teoh JY, Ng CF. Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective. Int Urol Nephrol. 2016;48(9):1429–35. https://doi.org/10.1007/s11255-016-1337-5 Epub 2016 Jun 2.

27. Wall HK, Ritchey MD, Gillespie C, Omura JD, Jamal A, George MG. Vital signs: prevalence of key cardiovascular disease risk factors for million hearts 2022 - United States, 2011-2016. MMWR Morb Mortal Wkly Rep. 2018;67(33):983–91. https://doi.org/10.15585/mmwr.mm6733a4.

28. Curigliano G, Lenihan D, Fradley M, et al. Electronic address: clinical-guidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. https://doi.org/10.1016/j.annonc.2019.10.023.

29. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56–62. https://doi.org/10.1200/JCO.2016.69.1378 Epub 2016 Oct 31.

30. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the international cardio-oncology society. Eur J Heart Fail. 2020;22(11):1945–60. https://doi.org/10.1002/ejhf.1920.

31. Jackson WC, Hartman HE, Dess RT, et al. Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: a network Meta-analysis of randomized trials. J Clin Oncol. 2020;38(26):3024–31. https://doi.org/10.1200/JCO.19.03217 Epub 2020 May 12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- Fast, convenient online submission
- Thorough peer review by experienced researchers in your field
- Rapid publication on acceptance
- Support for research data, including large and complex data types
- Gold Open Access which fosters wider collaboration and increased citations
- Maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions